Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

被引：0
|
作者：
Lin, C-C. [1 ]
Schneider, R. [2 ]
Gutierrez, M. [3 ]
Shen, L. [4 ]
Chung, K. [5 ]
Doroshow, D. B. [6 ]
Gao, B. [7 ,8 ]
Millward, M. [9 ]
Hsieh, C-Y. [10 ]
Xu, C. [10 ]
Cai, S. X. [10 ]
Tian, Y. E. [10 ]
Liu, L. [10 ]
Shen, C. [10 ]
Tan, Y. [10 ]
He, Y. [10 ]
Zhang, C. [10 ]
Li, L. [11 ]
Ma, M. [10 ]
Xu, L. [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Mary Crowley Canc Res, Dept Med Oncol, Dallas, TX USA
[3] Hackensack Univ, Dept Med Oncol, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[4] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[5] Prisma Hlth Syst Upstate, Clin Res, Inst Translat Oncol Res, Greenville, SC USA
[6] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA
[7] Blacktown Hosp, Haematol & Canc Care Ctr, Blacktown, NSW, Australia
[8] Univ Sydney, Blacktown, NSW, Australia
[9] Linear Clin Res, Oncol, Perth, WA, Australia
[10] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China
[11] IQVIA RDS Shanghai Co Ltd, Beijing Branch, Med, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
632P
引用
收藏
页码：S503 / S504
页数：2
相关论文
共 50 条
  • [31] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.
    Hong, David S.
    Garrido-Laguna, Ignacio
    Krop, Ian E.
    Subbiah, Vivek
    Werner, Theresa Louise
    Cotter, Christine M.
    Hamilton, Erika Paige
    Velastegui, Karen
    Xuan, Dawei
    Bugarini, Roberto
    Gollerkeri, Ashwin
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04) : 455 - E121
  • [34] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [35] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Joerger, Markus
    Calvo, Emiliano
    Laubli, Heinz
    Lopez, Juanita
    Alonso, Guzman
    de la Fuente, Elena Corral
    Hess, Dagmar
    Konig, David
    Perez, Vicky Sanchez
    Bucher, Christoph
    Jethwa, Sangeeta
    Garralda, Elena
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [36] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [37] First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
    Yap, Timothy A.
    Tolcher, Anthony W.
    Plummer, Ruth
    Mukker, Jatinder Kaur
    Enderlin, Marta
    Hicking, Christine
    Grombacher, Thomas
    Locatelli, Giuseppe
    Szucs, Zoltan
    Gounaris, Ioannis
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2057 - 2067
  • [38] Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors
    Meng, Yanchun
    Zhang, Jian
    Zhao, Chuanhua
    Cheng, Ying
    Zhu, Liming
    Song, Zhengbo
    Xu, Nong
    Wang, Zhen
    Wang, Yanping
    Du, Yiqun
    Jing, Deqiang
    Chen, Dinglu
    Qu, Qiaofeng
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.
    Matulonis, Ursula A.
    Janku, Filip
    Moser, Justin C.
    Fu, Siqing
    Wages, David S.
    Wheeler, Catherine A.
    Mori, Mikinaga
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Cheung, Kin
    Madden, Timothy
    Maier, Gary
    Johansen, Mary
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
    Gutierrez, M.
    Garralda, E.
    Calvo, E.
    van Dongen, M.
    Eskens, F. A.
    Finlay, M.
    Menas, F. Z.
    Zhu, C.
    Wu, M.
    Guillemin-Paveau, H.
    Abbadessa, G.
    Perez, R.
    Yildirim, O.
    Naing, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S646 - S647
12345